Viyash Scientific Limited has received the requisite approval from Italian authorities regarding its proposed acquisition of BioForLife Italia S.r.l. The regulatory clearance pertains to applicable FDI and Golden Power regulations in Italy.

The transaction involves the purchase of 100% shareholding in the Milan-based entity by Alivira Animal Health Limited, a step-down wholly owned subsidiary of Viyash Scientific based in Ireland.

Revised Timeline

Following the receipt of this approval, Viyash Scientific has revised the expected timeline for the completion of the transaction. The company stated that the deal is now expected to be completed within two months from the date of the intimation issued on September 8, 2026.

This update follows earlier disclosures made by the company on June 8, 2026, and July 21, 2026. Management confirmed that all other material terms and conditions set out in those previous disclosures remain unchanged.

Regulatory Compliance

The intimation was filed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company noted that customary closing formalities and conditions remain to be fulfilled before the finalization of the deal.

Promoters of Viyash Scientific sold a combined 5,03,65,847 equity shares in open market transactions on August 26, 2026. The disposal was executed by two promoter entities, CA Harbor Investments and CA Hull Investments.

The sale reduces the promoters' aggregate holding in the company. CA Harbor Investments sold 2,47,61,691 shares, while CA Hull Investments disposed of 2,56,04,156 shares. Both entities are Mauritius-based and directed by Santosh K Gujadhur.

Shareholding Changes

The transaction impacts the promoter group's voting power in Viyash Scientific. Before the sale, CA Harbor held 13,16,80,103 shares (30.14% of total share capital) and CA Hull held 13,61,60,231 shares (31.17%).

Post-transaction, CA Harbor's stake fell to 24.47% of total share capital, while CA Hull's holding dropped to 25.31%. In terms of diluted voting capital, CA Harbor's stake reduced from 27.44% to 22.28%, and CA Hull's from 28.37% to 23.03%.

Regulatory Disclosure

The companies filed the disclosure under Regulation 29(2) read with Regulation 29(3) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing confirms that CA Harbor and CA Hull are persons acting in concert with each other.

No encumbrances, pledges, or liens were reported on the shares held by either entity before or after the transaction. The total equity share capital of Viyash Scientific remains unchanged at ₹87,37,50,954, comprising 43,68,75,477 equity shares of face value ₹2 each.